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Multipotent mesenchymal stromal cells (MSCs) are used to improve the outcome of hematopoietic stem cell
transplantation (HCST) and in regenerative medicine. MSCsmay harbor persistent viruses that may compro-
mise their clinical benefit, however. Retrospectively screened, 1 of 20 MSCs from healthy donors contained
parvovirus B19 (B19) DNA. MSCs express the B19 receptor (P antigen/globoside) and a co-receptor (Ku 80)
and can transmit B19 to bonemarrow cells in vitro, suggesting that the virus can persist in the marrow stroma
of healthy individuals. Two patients undergoing HSCTreceived the B19-positive MSCs as treatment for graft-
versus-host disease; neither developed viremia nor symptomatic B19 infection. These findings demonstrate
for the first time that persistent B19 in MSCs can infect hematopoietic stem cells and underscore the impor-
tance of monitoring B19 transmission by MSC products.
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Multipotent mesenchymal stromal cells (MSCs)
are nonhematopoietic cells present in the human
bone marrow (BM) [1]. MSCs can be readily cultured,
have extensive proliferative capacity, and can differen-
tiate into more mature lineages, such as fat, cartilage,
and bone, prompting clinical trials usingMSCs for tis-
sue engineering [2-5]. These cells seem to have immu-
nomodulatory properties; MSC infusions have been
found to reverse therapy-resistant grade IV acute
graft-versus-host disease (GVHD) of the skin, gut,
and liver [6,7]. The risk of transmitting viruses from
ex vivo expanded MSCs is of particular concern in he-
matopoietic stem cell transplantation (HSCT) recipi-
ents with severe GVHD, because these individuals,
in whom GVHD-associated immunodeficiency is
compounding the effect of multiple immunosuppres-1172sive agents, are at particular risk for viral infection
[8-10]. We have found that MSCs are permissive for
herpes simplex virus and cytomegalovirus (CMV)
infections, but not for Epstein-Barr virus (EBV) infec-
tion. Herpes viruses have not been found in MSCs
derived from healthy donors, however [11].
Parvovirus B19 (B19) is a nonenveloped, single-
stranded DNA virus with pronounced tropism for ery-
throid precursors and megakaryocytes that express the
erythrocyte P antigen (globoside), known as the B19
receptor [12]. The a5b1 integrin (fibronectin) and
the Ku80 autoantigen have been described as B19 co-
receptors [13,14]. The replication of B19 is restricted.
Only a few permissive cell lines have been described,
including erythroleukemic and megakaryoblastoid
cell lines [15,16]. B19 is common worldwide, and the
seroprevalence increases with age, affecting 15% of
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tion in children can manifest as erythema infectiosum
(so-called ‘‘fifth disease’’), which is normally self-limit-
ing with mild symptoms and results in lifelong immu-
nity [17]. Clearance of the virus is slow and largely
mediated by neutralizing antibodies [18]. Primary in-
fection with B19 can cause aplastic crises in individuals
with high red cell turnover and chronic red cell aplasia,
or even severe pancytopenia in immunocompromised
individuals [17,19]. The virus is resistant to inactiva-
tion used in the procurement of blood and hematopoi-
etic stem cell (HSC) products, leading to a known risk
of B19 transmission [20]. Thus, patients naı¨ve to B19
with hypogammaglobulinemia after HSCT are at risk
for severe cytopenias [17].
Endothelial cells and fetal myocytes have been re-
ported to host B19 [21,22]. The virus can persist in the
BM, and recently has been detected in MSCs from
healthy donors [23-25]. Consequently, in the present
work, we screened clinical-grade MSC products used
to treat patients with GVHD for the presence of B19
and found persistent B19 in MSCs that could infect
HSCs cells in vitro.We found no clinical consequences
of MSC infusions containing B19 in immunocompro-
mised recipients, however.
SUBJECTS AND METHODS
Donors and Recipients
TheMSC donors (n5 20) were selected randomly
and considered healthy after assessment ofmedical his-
tory, physical examination, and serologic screening for
human immunodeficiency virus (n 5 20), hepatitis vi-
ruses (n5 20), and herpes viruses (n5 15). The recip-
ients underwent HSCT at the Center for Allogeneic
Stem Cell Transplantation, Karolinska University
Hospital Huddinge, between 2002 and 2006. MSCs
were used for prophylaxis or treatment of GVHD.
Second- and/or third-passage MSCs were given in
dosages of 1 to 2 106/kg. Patients who received
the B19-contaminated cells were assessed retrospec-
tively for persistent anemia, leukopenia, thrombocyto-
penia, rash, or arthritis, possibly related to B19
infection. Donors and recipients gave informed con-
sent, and the study design was approved by the
Regional Ethics Review Board.
Isolation and Ex Vivo Culture of MSCs
To isolate MSCs, BM aspirates (mean, 50 ml;
range, 16 to 80 mL) were obtained from the iliac crest
of healthy donors. The donors were 9 males and 11 fe-
males, with a median age of 40 years (range, 24 to 66
years). The clinical-grade MSC expansion was per-
formed according to the guidelines of the MSC Con-
sortium of the European Blood and Marrow
Transplantation Group and with the approval of theSwedish Medical Products Agency, as described in de-
tail previously [7,26].
To assess the growth of the MSCs, time to first
passage and doubling time in the first and second pas-
sages were recorded. The doubling time was calculated
using the following equation: doubling time 5 t/(log2
(y/x)), where t is the time in culture, y is the cell count at
confluence, and x is the cell count at start. Adipogenic
and osteogenic differentiation after induction were
evaluated as described previously [27].
Characterized by flow cytometry, the MSCs uni-
formly fulfilled MSC criteria [1]. The MSC suspen-
sions were culture-negative for bacteria and fungi,
and polymerase chain reaction (PCR)-negative forMy-
coplasma pneumonia [7,26].
PCR Detection of B19 DNA and Anti-B19 IgG
Serology
For quantification of parvovirus B19 DNA, a hu-
man parvovirus genotype 1-, 2-, and 3-specific Taq-
Man real-time PCR assay was used, as described
previously [18]. DNA from 105 MSCs and DNA
from 200 mL of serum samples were extracted using
an automated MagnaPure extractor (Roche Diagnos-
tics Scandinavia, Stockholm, Sweden) using the LC
Total Nucleic Acid Isolation Kit (Roche Diagnostics
Scandinavia). Serum samples were analyzed for anti-
B19 IgG using a commercial EIA (Biotrin Interna-
tional, Dublin, Ireland).
Isolation of Peripheral Blood Lymphocytes and
Mixed Lymphocyte Cultures
Peripheral blood lymphocytes were isolated from
the HSCT recipients who received the B19-positive
MSCs and were used in mixed lymphocyte reactions
(MLRs) to evaluate the responsiveness to allogeneic
cells, as described elsewhere [11,28].
Determination of PAntigen, Ku80, and
Glycophorin A Expression
The expression of P antigen by MSCs was deter-
mined by flow cytometry. MSCs were incubated with
plasma from an individual with anti-P antigen anti-
bodies (optimized to 1/20; anti-PP1Pk [ie, anti-Tja],
blood group AB Rh-positive without anti-HLA anti-
bodies;Department ofTransfusionMedicine,Karolin-
ska University Hospital Huddinge) and polyclonal
rabbit anti-globoside antibody (optimized to 1/10;
Matreya, Pleasant Gap, PA), respectively. Thereafter,
the MSCs were incubated with monoclonal fluorescei-
nated anti-human immunoglobulin antibodies (opti-
mized to 200 mg/mL; Jackson ImmunoResearch
Laboratories, West Grove, PA) and anti-rabbit immu-
noglobulin (optimized to 100 mg/mL; Sigma-Aldrich,
St Louis,MO), respectively. The plasma from the indi-
vidualwith anti-P antigen antibodies alsowas used after
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as a specificity control. Ku80 expression was investi-
gated using a monoclonal mouse anti-Ku80 antibody
(optimized to 20 mg/mL; Abcam, Cambridge, UK)
and a monoclonal anti-mouse antibody (optimized to
200 mg/mL; Jackson ImmunoResearch Laboratories).
Glycophorin A (CD235a) expression was determined
by incubation with a monoclonal phycoerythrin-
labeled anti-CD235a antibody (optimized to 2 mg/mL;
BD Biosciences, San Jose, CA). In all experiments, 6
MSCs were tested, and 3 BM cells were used as control
cells. Finally, labeled cellswere assayed in aflowcytom-
eter (BD Biosciences). Fluorescence signals from 5
104 cells were counted, and the percentage of fluores-
cence-positive cells was determined.
Evaluation of B19 Transmission
To evaluate possible transmission of B19, the B19-
positive adherent MSCs were co-cultured in RPMI
1640 medium supplemented with 2 mM HEPES,
100 U/mL of penicillin, 100 mg/mL of streptomycin,
2 mM L-glutamine (Gibco-BRL, Life Technologies,
Paisley, UK), and 10% heat-inactivated pooled human
AB serum, with P antigen–positive BM cells (n5 3) in
suspension for 3 days. BM cells incubated with B19-
rich plasma (lot BPL9, with 10 genomic equivalents
[geq]/target cell, kindly provided by Dr Kerr, Biotrin
International) were used as controls. Adherent B19-
negative MSCs (n 5 3) also were co-cultured with
the B19-positive MSCs in transwell inserts (1:1) and,
as a control, the MSCs were exposed to B19-rich
plasma (10 geq/cell). In an additional assay, blocking
of possible B19 transmission was investigated using
anti-B19 antibodies (optimized to 4 mg/mL; Santa
Cruz Biotechnology, Santa Cruz, CA) in a culture
medium of B19-positive MSCs/BM cell co-cultures
(n 5 3) for 3 days. BM cells were dried on
microscopy slides, and adherent MSCs were cultured
on slides. Both types of slides were fixed in a metha-
nol-acetone solution at 220 C. Slides were stained
with a mouse anti-B19 antibody (optimized to 2 mg/
mL; Santa Cruz Biotechnology) and a secondary fluo-
resceinated anti-mouse immunoglobulin antibody
(optimized to 100 mg/mL; Jackson ImmunoResearch
Laboratories). After the slides were mounted with
medium containing 4’,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories, Burlingame, CA) to visu-
alize the nuclei, they were read independently by 2 of
the authors. For slides with BM cells and MSCs,
more than 500 and 150 cells were counted, respec-
tively, and the percentage of fluorescein-positive cells
was determined. The analysis was performed using
a DMRXA fluorescence microscope (Leica Microsys-
tems,Wetzlar, Germany) at 22Cwith a 40 oil objec-
tive (PL Fluotar Oil; Leica Microsystems) and filters
for fluorescein andDAPI (ChromaTechnology, Rock-ingham, VT). Images were captured using a camera (S/
N 370 KL 0565; Cooke Corp, Romulus, MI) and Sli-
deBook 2.1.5 software (Intelligent Imaging Innova-
tions, Denver, CO). Finally, images were
postprocessed and mounted using Photoshop 3.0
(Adobe Systems, San Jose, CA).
RESULTS
Expected Serologic Results of the Donors and
Presence of B19 DNA in MSCs From a Donor
Serologic investigation of anti-B19 IgG was possi-
ble in 75% (15/20) of the donors included in this study
who demonstrated a seroprevalence of 47%. DNA was
successfully extracted from donor serum and MSCs
(data not shown). None of the donors had B19 DNA
present in their serum; however, in 1 of the seroposi-
tive donor MSCs (K11), B19 DNA was present in 1
 103 geq/105 cells.
No Differences in MSC Growth and Phenotype
The B19 DNA–positive MSCs required 14 days in
culture to first passage. This was within the range of 8
to 18 days found for the other 19MSCs. Similarly, cell
doubling time (mean 6 standard deviation) was com-
parable in the first and second passages (3.1 and 4.1
days, respectively, for the B19 DNA–positive MSCs,
compared with 3.7 6 1.7 and 3.6 6 0.8 days, respec-
tively, for the B19-negative MSCs). Cells from sero-
negative and seropositive donors exhibited doubling
times of 4.4 6 1.9 and 3.0 6 1.0 days, respectively,
in the first passage and 3.7 6 0.7 and 3.6 6 0.9 days,
respectively, in the second passage.
All expanded MSCs exhibited the same phenotype
assessed by flow cytometry of surface markers. No dif-
ferences in differentiation between the B19-positive
MSCs and the other MSCs were demonstrated by
morphological examination and spectrophotometry.
This was also true of MSCs from seronegative donors
and MSCs from seropositive donors (data not shown).
MSCs Express PAntigen and Ku80, but not
Glycophorin A
We used flow cytometry to detect P antigen on
MSCs, using plasma from a subject with anti-P anti-
bodies and a commercial anti-globoside antibody. P
antigen was expressed by all MSCs tested (n 5 6), but
less strongly than on BM cell controls (n 5 3). MSCs
displayed low expression using the anti-P antibody
plasma or the commercial anti-globoside antibody,
whereas BM cells displayed high expression. After ab-
sorption (with erythrocytes) of the anti-P antibody
plasma, MSC expression was reduced to background
(secondary antibody). The B19 PCR-positive MSC
K11 displayed low expression using the anti-globoside
Biol Blood Marrow Transplant 14:1172-1179, 2008 1175Parvovirus B19 in Multipotent Mesenchymal Stromal CellsFigure 1. P antigen, Ku80, and glycophorin A expression in MSCs determined by flow cytometry. Unfractioned BM cells (A) and MSCs (B) expressed P
antigen as investigated by a commercial anti-globoside antibody; however, the MSCs were less positive than the BM cells. Expression of P antigen on
MSCs also could be demonstrated using patient plasma with anti-P antigen antibodies (C). The specificity of the plasma was determined by reduction
of positivity after absorption with erythrocytes (D). Unfractioned BM (E) and MSCs (F) expressed Ku80, although MSCs at slightly higher levels. Un-
fractioned BM cells expressed glycophorin A (G), whereas MSCs exhibited only weak positivity (H). Matched isotype controls defined the quadrants.
Values on the y-axis indicate intensity log. Representative dot plots of cells from 6 different donors are shown.antibody. All MSCs expressed Ku80 at higher levels
than found in BM cells. In contrast to BM cells, which
displayed high expression of glycophorin A using the
anti-glycophorin A antibody,MSCs displayedminimal
levels (Figure 1).MSCs Can Transmit B19 to BM Cells In Vitro
BM cells from 3 individuals exposed to B19-rich
plasma for 3 days were 10%, 11%, and 12% positive,
respectively, for intracellular B19 antigen by immu-
nofluorescence. In comparison, nonexposed cells
1176 Biol Blood Marrow Transplant 14:1172-1179, 2008M. Sundin et al.Figure 2. Parvovirus B19 immunostaining to investigate transmission from MSCs. (A) Unexposed BM cells were negative for B19. (B) BM cells incu-
bated with B19-rich plasma were positive (green) for B19 fluorescence. (C) Transmission of B19 was demonstrated, because positive cells could be de-
tected after B19-negative BM cells were co-cultured with B19-positive MSCs. (D) The transmission of B19 could be inhibited by adding anti-B19
antibodies to the co-culture medium. (E) UnexposedMSCs were negative for B19. (F) MSCs incubated with B19-rich plasmawere positive for B19 green
grainy fluorescence. (G) No transmission of B19 from the B19-positive MSCs to B19-negative MSCs was detected after co-culture. Representative
photos are shown.were \ 1% positive for the antigen (Figure 2). In
parallel, when the BM cells from these subjects
were co-cultured with the B19-positive MSC K11,
6%, 6%, and 7% of the cells, respectively, were pos-
itive for B19 by immunofluorescence. In contrast, co-
cultures to which anti-B19 antibodies was addedshowed only background (\ 1%) fluorescence.
B19-exposed MSCs demonstrated reduced viability
(ie, low number of cells) compared with the unex-
posed or antibody-treated controls.
Immunofluorescence analysis of the B19 PCR-
positive MSCs resulted in 3% positive cells. Exposure
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Patient
Unique patient number 1044 1082
Sex/age, years Male/60 Female/65
Diagnosis Myeloma Chronic lymphocytic leukemia
HSCT
HLA match HLA-identical sibling HLA-identical sibling
Conditioning RIC: Flu + TBI RIC: Flu + Cy
Cell source PBSC PBSC
GVHD prophylaxis CsA + MMF CsA + MTX
Day of GVHD diagnosis 51 25
Grade of acute GVHD III III
MSC transplantation
Indication GVHD GVHD
HLA match MM MM
Day of first MSC infusion 77 32
Number of MSC infusions 1 3*
MSC passage 2 2+3/3/2+3
MSC dose, 106/kg 0.9 1.7/1.7/0.9
GVDH response to MSC infusion CR PR
B19 investigations and symptoms
HSC donor anti-parvovirus B19 IgG serology + -
HSC donor serum load of parvovirus B19 DNA, 103 geq/mL - -
Recipient anti-parvovirus B19 IgG serology, pretreatment - +
Recipient anti-parvovirus B19 IgG serology, 1 month posttreatment - -
Recipient anti-parvovirus B19 IgG serology, 3 months posttreatment - -
Recipient serum load of parvovirus B19 DNA, 103 geq/mL, pretreatment - -
Recipient serum load of parvovirus B19 DNA, 103 geq/mL, 1 month posttreatment - -
Recipient serum load of parvovirus B19 DNA,103 geq/mL, 3 months posttreatment - -
Clinical symptoms of parvovirus B19 disease None None
Recipient immunocompetence at MSC transplantation
Lymphocyte proliferation in allogeneic MLC, % of positive control 22% 14%
IgG level, g/L (reference interval, 6.1 to 14.9) 3.4 5.1
IgA level, g/L (reference interval, 0.88 to 4.5) 0.41 0.91
IgM level, g/L (reference interval, 0.27 to 2.10) 0.49 0.34
White blood cell count, 109/L (reference interval, 3.5 to 8.8) 8.7 1.8
Absolute neutrophil count, 109/L (reference interval, 1.6 to 7.5) 7.6 0.8
Blood parameters†
Hemoglobin, g/L (reference interval: females, 117 to 153; males, 134 to 170) 95/90/85 114/117/124
White blood cell count, 109/L (reference interval, 3.5 to 8.8) 8.7/5.4/5.0 1.8/9.1/9.9
Platelet count, 109/L (reference interval: females, 165 to 387; males, 145 to 348) 104/119/78 55/96/92
Outcome Deceased, relapse,day 773 Deceased, septicemia, fungi, day 120
Flu indicates fludarabine; TBI, total body irradiation; Cy, cyclophosphamide; PBSC, HSCs mobilized to peripheral blood; CsA, cyclosporine A; MMF, my-
cofenolate mofetil; MTX, methotrexate; MM, HLA-mismatched unrelated; CR, complete response; PR, partial response.
*Patient 1082 received 3 MSC infusions. The first infusion was MSC K11, which later was found to be contaminated with parvovirus B19.
†Measured at the time of MSC infusion and approximately 1 and 2 weeks after MSC infusion.of MSCs from 3 donors to B19-rich plasma resulted in
41%, 48%, and 58% B19-positive MSCs, respectively,
compared with background levels (\2%) in unexposed
controls, and could be blocked by anti-B19 antibodies.
We did not observe transmission of B19 from the B19-
positive MSCs to 3 B19-negative MSCs in transwell
co-cultures.
Clinical Outcome of Recipients of Parvovirus-
Contaminated MSCs
MSC K11 (B19-positive by PCR) was adminis-
tered to 2 subjects in a clinical trial to treat severe re-
fractory acute GVHD (aGVHD). Characteristics of
the subjects, HSCT, and MSC therapy are given in
Table 1. One of the donor–recipient pairs was mis-
matched in terms of B19 serology. B19 could not be
detected by PCR in either donors or recipients before
HSCT. Both recipients were immunocompromised
due to leukopenia, subnormal immunoglobulin levels,and poor responses inMLRs; however, neither had any
clinical signs of B19 infection. Their blood counts re-
mained stable, no B19 seroconversion occurred, and
no B19 DNA was detected in the blood after MSC
transplantation. The patients died, one due to relapse
and the other due to septicemia, neither of which was
likely related to infusion of B19-positive MSCs.
DISCUSSION
Plentz el al. [20] showed that 1% of all blood prod-
ucts are positive for B19 DNA, with the highest inci-
dence (17.6%) found in HSCs mobilized to the
periphery and in BM. Therefore, many manufacturers
of blood and plasma derivates screen their products for
B19 by quantitative PCR [29]. B19 infection could
pose a risk for severe cytopenia in immunosuppressed
HSCT recipients [30]. Because B19 has been reported
1178 Biol Blood Marrow Transplant 14:1172-1179, 2008M. Sundin et al.to occur in BM–derivedMSCs [23], we retrospectively
screened for B19 in MSCs used to treat GVHD in 20
HSCT recipients. Anti-B19 IgG was detected in about
50% of the healthyMSC donors, which correlates with
the estimated seroprevalence in the adult population
[17]. None of the MSC donors was viremic; they all
tested negative for B19 DNA in serum. B19 DNA
was found in MSCs from 1 donor, however. Hemato-
poietic contamination was not the likely source of B19,
because the presence of such cells is excluded by flow
cytometry before clinical MSC batches are released.
Cassinotti et al. [24] demonstrated that B19 can persist
in the BM of healthy and asymptomatic individuals.
Cells expressing the P antigen are permissive for B19
entry [12,31]. In the absence of P antigen, the a5b1 in-
tegrin and the Ku80 can serve as B19 co-receptors
[13,14]. a5b1 integrin expression on MSCs was re-
ported recently [32]. Consequently, we tested MSCs
from 6 donors, including the B19-positive cells, for
surface expression of P antigen and Ku80. All MSCs
expressed the antigens/B19 receptors. To clarify
whether the MSCs share other features of erythroid
cells, glycophorin A expression was measured, but
was found to be minimal.
The B19-positive MSCs infected BM cells in
a manner similar to B19-rich plasma. MSCs also could
be infected by the B19-rich plasma, but they exhibited
poor survival, suggesting a cytopathic effect. The B19
DNA–positive MSCs could not infect other MSCs,
however. This may be explained by low virus concen-
trations, because the B19-rich plasma could infect the
MSCs, along with weaker expression of P antigen on
MSCs than on BM cells. Furthermore, B19- positive
and -negative MSCs were separated in a transwell sys-
tem, preventing cell-to-cell contact, which may be re-
quired for viral transmision. Compared with BM cells,
MSCs exposed to B19-rich plasma showed stronger
positivity for B19 antigens by immunofluorescence.
This may be explained by the relatively higher prolif-
erative and metabolic activity of ex vivo–cultured
MSCs. We have shown that MSCs are permissive to
some extent. B19 is known to have an extreme tropism
for human erythroid cells, and only a few cell lines sup-
port semipermissive infection in vitro [15,16]. Re-
cently, Wong et al. [33] reported that ex vivo–
generated CD361 erythroid progenitors may be used
to study B19 replication. The unavailability of in vitro
culture systems for productive growth of B19 has lim-
ited this research thus far. The inhibition of B19 trans-
mission by anti-B19 antibodies suggests that
endogenous B19-neutralizing antibodies or intrave-
nous administration of pooled immunoglobulins may
be protective in vivo. Thus,MSCsmay be a natural res-
ervoir for persistent B19. This is in analogy with the
findings of Scadden et al. [34], who described BM stro-
mal cells as an HIV reservoir, passing the virus to both
myelogenous and lymphoid cells. Thus, MSCs and theBM stroma might be sites of persistent viruses. In the
absence of reliable long-term culture systems to gener-
ate B19 in vitro, MSCs, which can be readily infected
by B19, could be used to propagate the virus long-
term. Our findings do not explain why only a small mi-
nority of seropositive individuals demonstrate viral
persistence in the marrow, however.
The viral load in the B19-positive MSCs was 1 
103 geq/105 cells, roughly comparable to the median
viral load of 0.7  103 geq/mL in blood components
reported by Plentz et al. [20]. Therefore, MSCs and
blood products should have comparable infectivity.
In the study by Plentz et al. [20], 12% of the patients
in a hematology ward (most of whomwere undergoing
HSCT) were exposed to B19-contaminated products.
No patients developed clinical disease, but 1 patient
developed viremia [20]. Here we report 2 heavily im-
munocompromised patients with severe GVHD who
were exposed to B19-contaminated MSCs. Both pa-
tients were within 3 months of HSCT with severe
GVHD. They were leukopenic and immunoglobu-
lin-deficient and demonstrated functional T lympho-
cyte deficiency by MLRs at the time of MSC
infusion. Neither patient developed clinical signs of in-
fection or had detectable B19 DNA or anti-B19 IgG
after MSC infusion, indicating the absence of infec-
tion. Possibly, the viral transmission was below the
threshold for established infection. In one case in
which the HSCT recipient developed B19 infection,
the donor was found to have asymptomatic viremia,
suggesting that much higher viral loads are required
[35]. Quantitative information relating viral load to in-
fectivity is lacking, however, and the risk of B19 infec-
tion in immunodeficient HSCT patients remains
unclear. The low immunoglobulin levels encountered
after transplantation might increase the risk of new in-
fection or of reactivation in asymptomatic carriers;
however, B19 infections do not constitute a major clin-
ical problem in HSCT recipients (or perhaps they are
underdiagnosed). Cytopenias and viral illness due to
primary or reactivated B19 infection have been de-
scribed previously [19]. B19-infected MSCs display
low viability, which also may explain the absence of in-
fection in our patients.
Our data support the possibility that B19 has low
pathogenicity even in highly immunosuppressed indi-
viduals receivingMSCs, which themselves may further
reduce immunity against viruses [11]. Nevertheless,
given the lack of data, it seems prudent to screen
MSC products from seropositive donors for B19
DNA and to administer only virus-negative products,
or, at a minimum, to infuse MSCs containing B19
only in patients with a measurable titer of antibodies
to B19. Further investigation of the relationship
between MSCs and viral persistence and screening
of MSC products for contaminating viruses are
warranted.
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